Longevity risk – the risk of insured individuals living longer than expected – is a thematic one in the life risk industry, having far-flung ramifications for insurance companies and capital markets participation in life risk. This month, Chris Anderson, Senior Manager, EMEIA Insurance – Risk and Actuarial Services in EY’s Edinburgh office discusses the impact of longevity from an actuarial sciences perspective.
Insurers are favouring funded re as it helps firms manage the market and longevity risks associated with writing bulk purchase annuity (BPA) business by reducing capital charges and therefore making PRT deals more competitive.
Unsurprisingly, given its growth and potential for capital optimisation, UK regulators have been carefully watching the increased use of funded re. In June 2023, the Prudential Regulatory Authority (PRA) sent a “Dear CRO’ letter to heads of risk at UK life insurers.
The letter outlined the regulator’s two main concerns from a sectoral review which it had carried out.
“One of the key risks arising in funded re is that firms recapture sub-optimal portfolios with depressed values and with limited ability to be transformed effectively to the firms’ preferred portfolio,” the PRA letter said.
Post a comment
Related Posts
Both Demand and Supply Factors Contribute to Rare Secondary Market Pullback in 2024
The life settlement secondary market suffered a rare pull back in aggregate transaction activity in…
Funded Reinsurance Under Scrutiny But Should Remain a Feature of the UK Pension risk Transfer Market
In the past 12 months or so, the Prudential Regulation Authority (PRA), the UK insurance…
Plenty of Guardrails for US Life Insurers Backing Group Annuities With Private Assets
There has been extensive coverage in the trade media in the past 12 months relating…
Liver Disease Mortality in England Continues to Worsen but General Mortality Still on a Post-Covid Downward Trend
The UK government’s Department of Health and Social Care (DHSC) maintains a Mortality Profile for…
